Publications by authors named "C S Zamora"
Eltrombopag (ELT) is a thrombopoietin-receptor agonist that stimulates platelet (PLT) production in patients with primary immune thrombocytopenia (ITP). One potential mechanism of ELT is modulating the inflammatory response by increasing PLTs binding to leucocytes. This study examined the effect of ELT on leucocyte-PLTs complexes in 38 ITP patients.
View Article and Find Full Text PDFArticle Synopsis
- Current SARS-CoV-2 mRNA vaccines are effective, but there's a need for new strategies due to waning immunity and variant emergence, prompting this study on a heterologous mRNA/MVA vaccination approach.
- The research demonstrates that a combination of a trimeric receptor binding domain (RBD) delivered via mRNA and a modified vaccinia virus (MVA) boost creates strong immune responses, including effective antibodies and T cell activity against various SARS-CoV-2 strains.
- The heterologous regimen provided complete protection in specific mouse models after exposure to the virus, outperforming traditional methods and suggesting that alternative nanocarrier technologies could enhance vaccine effectiveness while avoiding patent issues.
Background And Purpose: Considering recent iodinated contrast shortages and a focus on reducing waste, developing protocols with lower contrast dosing while maintaining image quality through artificial intelligence is needed. This study compared reduced iodinated contrast media and standard dose CTP acquisitions, and the impact of deep learning denoising on CTP image quality in preclinical and clinical studies. The effect of reduced X-ray mAs dose was also investigated in preclinical studies.
View Article and Find Full Text PDFArticle Synopsis
- PD-(L)1 inhibitors are used to treat non-small cell lung cancer (NSCLC), but their effectiveness varies among patients.
- This study analyzed PD-L1 expression in circulating leukocytes in 113 NSCLC patients to determine who might benefit from these inhibitors, focusing on their responses after 10-12 weeks of treatment.
- Results showed that responders to treatment had higher pre-treatment levels of specific PD-L1 expressing cells, and post-treatment levels decreased, suggesting that measuring these markers before treatment could help identify suitable candidates for anti-PD-(L)1 therapy.